

Faron Pharmaceuticals Ltd.

("Faron" or "the Company")

Faron announces Capital Markets Day to be held on 22 October 2024

Press release, 7 October 2024

TURKU, FINLAND- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that it will host a Capital Markets Day for investors, analysts and media on Tuesday, 22 October 2024 at 08:00 am (EDT) / 13:00 pm (BST) / 15:00 pm (EEST). Speakers include Dr. Mika Kontro, MD, PhD, Associate Professor at the University of Helsinki, Mr. Ralph Hughes, MSc, BSc, Senior Vice President at PharmaVentures and members of Faron's senior management team.

The agenda is as follows:

- Opening remarks
- Faron's strategy and key focus areas - Dr. Juho Jalkanen, MD, PhD, CEO
- BEXMAB clinical data - Dr. Mika Kontro, MD, PhD, principal investigator of the BEXMAB trial
- BEXMAB MDS market assessment - Mr. Ralph Hughes, MSc, BSc
- Faron's development plan for solid tumors - Dr. Petri Bono, MD, PhD, CMO
- Who benefits from *bexmarilimab* and why - Future Addressable Markets - Dr. Maija Hollmén, PhD, CSO
- Q&A session
- Closing remarks

As part of the event, Juho Jalkanen, CEO of Faron, will discuss Faron's strategy and key focus areas for the coming years. Dr. Kontro will share updated survival data from the ongoing BEXMAB Phase I/II trial. Mr. Hughes will present the results of recently conducted market research in MDS. Dr. Bono will provide Faron's development plan for solid tumours, discuss *bexmarilimab*'s further potential as first-in-class immune-oncological treatment and introduce the Company's new Scientific Advisory Board (SAB).

"I am delighted to be hosting this Capital Markets Day with our invited speakers and members of Faron's senior management team who will provide important insights into the recent developments and further plan to bring the promise of immunotherapy to a broader patient group," said Dr. Juho Jalkanen, Chief Executive Officer of Faron. "In addition to providing the latest BEXMAB survival update, we will present the clinical development plan for *bexmarilimab* in solid tumors. The event will also feature an introduction to our new Scientific Advisory Board with world-leading clinical investigators," said Dr. Petri Bono, Chief Medical Officer at Faron.

The event will be held as a live hybrid event. It will begin at 08:00 am (EDT) / 13:00 pm (BST) / 15:00 pm (EEST) on Tuesday, October 22, 2024. The duration of the event will be some 2.5 hours.

Webcast registration link: <https://faron.videosync.fi/cmd-2024>

Live participation

In addition to the webcast, there are a limited number of seats available to attend the Capital Markets Day at Eliel in Sanomatalo at Töölönlahdenkatu 2, Helsinki. To register, please contact investor.relations@faron.com no later than 2:00 pm (EEST) on Friday, 18 October 2024. Please note that places are limited, and you will receive a separate email if you get a seat confirmed.

A link to a recording of this Capital Markets Day will be made available on the "Investors" section on Faron's website at: <https://www.faron.com/investors>.

For more information please contact:

ICR Consilium

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880

Peel Hunt LLP, Broker

Christopher Golden, James Steel
Phone: +44 (0) 20 7418 8900

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990

About BEXMAB

The BEXMAB study is an open-label Phase I/II clinical trial investigating *bexmarilimab* in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of *bexmarilimab* in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes.

About *bexmarilimab*

Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. *Bexmarilimab* binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, *bexmarilimab* alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is *bexmarilimab*, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. *Bexmarilimab* is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAUNOWRSKURRAA